24 results on '"KyungAh Im"'
Search Results
2. REDUCTION IN TOTAL CARDIOVASCULAR EVENTS WITH THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH CARDIOVASCULAR DISEASE IN THE COMBINED FOURIER AND FOURIER OPEN-LABEL EXTENSION (OLE) STUDIES
- Author
-
Sabina Murphy, Michelle L. O'Donoghue, Stephen Wiviott, Dan Atar, Anthony C. Keech, Julia Kuder, KyungAh Im, Jose Flores-Arredondo, J. Antonio, G. Lopez, Mary Elliott, Bei Wang, Maria Laura Monsalvo, Siddique A. Abbasi, Robert P. Giugliano, and Marc Steven Sabatine
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2023
3. Cognition After Lowering LDL-Cholesterol With Evolocumab
- Author
-
Brian R. Ott, Fourier Investigators, Marc S. Sabatine, KyungAh Im, Huei Wang, Jianping Guo, Baris Gencer, Anthony C Keech, Christopher E. Kurtz, Terje R. Pedersen, Robert P. Giugliano, François Mach, and Andrea Ruzza
- Subjects
Adult ,Male ,medicine.medical_specialty ,Statin ,medicine.drug_class ,030204 cardiovascular system & hematology ,Antibodies, Monoclonal, Humanized ,Placebo ,03 medical and health sciences ,chemistry.chemical_compound ,Cognition ,0302 clinical medicine ,Double-Blind Method ,Internal medicine ,medicine ,Humans ,Cognitive Dysfunction ,030212 general & internal medicine ,Effects of sleep deprivation on cognitive performance ,Cognitive decline ,Aged ,Aged, 80 and over ,business.industry ,Cholesterol ,Anticholesteremic Agents ,PCSK9 ,Cholesterol, LDL ,Middle Aged ,Atherosclerosis ,Evolocumab ,chemistry ,Cardiovascular Diseases ,Drug Therapy, Combination ,Female ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Cardiology and Cardiovascular Medicine ,business - Abstract
The EBBINGHAUS (Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects) trial demonstrated that evolocumab added to a background statin did not affect cognitive performance in a subset of 1,204 patients enrolled in FOURIER (Further Cardiovascular Outcomes Research With PCSK9 inhibitors in Subjects With Elevated Risk).The authors describe patient-reported cognition in the entire FOURIER trial using a self-survey.FOURIER was a randomized, double-blind, placebo-controlled trial involving patients with atherosclerotic cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) levels ≥70 mg/dl or non-high-density cholesterol ≥100 mg/dl despite statin therapy. At the final visit, patients completed a 23-item survey on memory and executive domains from the Everyday Cognition (ECog) scale. Patients compared their levels of everyday function at the end of the trial with their levels at the beginning and scored as 1 (no change or improvement), 2 (occasionally worse), 3 (consistently little worse), or 4 (consistently much worse). ECog scores were compared by the 2 randomized treatment arms and by achieved LDL-C at 4 weeks.A total of 22,655 patients completed ECog after a median duration of 2.2 years. The proportions of patients reporting cognitive decline (ECog score ≥2) at the end of the study were similar for placebo versus evolocumab, both for total score 3.6% versus 3.7% (p = 0.62) and for subdomains (memory, 5.8% vs. 6.0%; total executive, 3.6% vs. 3.7%). The proportion of patients reporting a decline in total cognitive score was similar among the 2,338 patients who achieved very low LDL-C levels (20 mg/dl) compared to the 3,613 patients with LDL-C ≥100 mg/dl (3.8% vs. 4.5%, p = 0.57).The addition of evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an average of 2.2 years of treatment, even among patients who achieved LDL-C 20 mg/dl.
- Published
- 2020
4. Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography
- Author
-
Marc S. Sabatine, Remo H.M. Furtado, Jianping Guo, L. Kristin Newby, KyungAh Im, Jose C. Nicolau, Jennifer A. White, and Robert P. Giugliano
- Subjects
Male ,medicine.medical_specialty ,Acute coronary syndrome ,030204 cardiovascular system & hematology ,Coronary Angiography ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,ST segment ,030212 general & internal medicine ,Myocardial infarction ,Acute Coronary Syndrome ,Non-ST Elevated Myocardial Infarction ,Aged ,Morphine ,business.industry ,Hazard ratio ,Odds ratio ,Middle Aged ,Clopidogrel ,medicine.disease ,Analgesics, Opioid ,Treatment Outcome ,Concomitant ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
Background Mechanistic studies have shown that morphine blunts the antiplatelet effects of oral adenosine diphosphate receptor blockers. However, the clinical relevance of this interaction is controversial. Objectives This study sought to explore the association between morphine and ischemic events in 5,438 patients treated with concomitant clopidogrel presenting with non-ST-segment elevation acute coronary syndromes (NSTEACS) in the EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome) trial. Patients not treated with clopidogrel (n = 3,462) were used as negative controls. Methods Endpoints were the composite of death, myocardial infarction (MI), recurrent ischemia, or thrombotic bailout at 96 h (4-way endpoint) and the composite of death or MI at 30 days. Results In patients treated with clopidogrel, morphine use was associated with higher rates of the 4-way endpoint at 96 h (adjusted odds ratio [OR]: 1.40; 95% confidence interval [CI]: 1.04 to 1.87; p = 0.026). There was a trend for higher rates of death or MI at 30 days (adjusted OR: 1.29; 95% CI: 0.98 to 1.70; p = 0.072), driven by events in the first 48 h (adjusted hazard ratio: 1.54; 95% CI: 1.07 to 2.23; p = 0.021). In patients not treated with clopidogrel, morphine was not associated with either the 4-way endpoint at 96 h (adjusted OR: 1.05; 95% CI: 0.74 to 1.49; p = 0.79; pinteraction = 0.36 ) or death or MI at 30 days (adjusted OR: 1.07; 95% CI: 0.77 to 1.48; p = 0.70; pinteraction = 0.46). Conclusions When used concomitantly with clopidogrel pre-treatment, morphine was associated with higher rates of ischemic events in patients with NSTEACS. (EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome; NCT00089895 )
- Published
- 2020
5. A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48
- Author
-
KyungAh Im, Howard Rutman, Elliott M. Antman, Christian T. Ruff, Minao Tang, Petr Jarolim, Robert P. Giugliano, David A. Morrow, David D. Berg, and Eugene Braunwald
- Subjects
Oncology ,Male ,Proteomics ,medicine.medical_specialty ,Pyridines ,MEDLINE ,Hemorrhage ,Risk Assessment ,Article ,Risk Factors ,Internal medicine ,Thromboembolism ,Atrial Fibrillation ,medicine ,Humans ,Randomized Controlled Trials as Topic ,business.industry ,Middle Aged ,Thromboembolic risk ,Thiazoles ,Female ,Cardiology and Cardiovascular Medicine ,business ,TIMI ,Biomarkers ,Factor Xa Inhibitors - Published
- 2021
6. Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial
- Author
-
Ilaria, Cavallari, Deepak L, Bhatt, Ph Gabriel, Steg, Lawrence A, Leiter, Darren K, McGuire, Ofri, Mosenzon, Kyungah, Im, Itamar, Raz, Eugene, Braunwald, and Benjamin M, Scirica
- Subjects
Male ,Dipeptidyl-Peptidase IV Inhibitors ,Adamantane ,Coronary Artery Disease ,Dipeptides ,Risk Assessment ,Death, Sudden, Cardiac ,Diabetes Mellitus, Type 2 ,Heart Disease Risk Factors ,Cause of Death ,Humans ,Female ,Mortality ,Biomarkers ,Aged - Published
- 2020
7. A TARGETED PROTEOMIC APPROACH IDENTIFIES NOVEL BIOMARKERS OF ARTERIAL THROMBOEMBOLIC RISK IN ENGAGE AF-TIMI 48
- Author
-
David Berg, Robert Giugliano, Christian Ruff, Minao Tang, KyungAh Im, Petr Jarolim, Howard Rutman, Elliott Antman, Eugene Braunwald, and David Morrow
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2021
8. Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes
- Author
-
C. Michael Gibson, Stephen D. Wiviott, Christopher P. Cannon, Amy Sarma, Robert P. Giugliano, L. Kristin Newby, KyungAh Im, Jianping Guo, Elliott M. Antman, Marc S. Sabatine, Michelle L. O'Donoghue, Eugene Braunwald, and David A. Morrow
- Subjects
Male ,medicine.medical_specialty ,030204 cardiovascular system & hematology ,Lower risk ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Myocardial infarction ,Acute Coronary Syndrome ,Stroke ,Randomized Controlled Trials as Topic ,Sex Characteristics ,Proportional hazards model ,business.industry ,Hazard ratio ,Absolute risk reduction ,medicine.disease ,Clinical Trials, Phase III as Topic ,Female ,Cardiology and Cardiovascular Medicine ,business ,Mace ,TIMI - Abstract
It remains disputed whether women are at excess risk of adverse outcomes versus men after non-ST-segment elevation acute coronary syndromes (NSTEACS) or whether differences are explained by discordant risk factors.A sex-specific analysis of cardiovascular outcomes after NSTEACS across trials conducted by the Thrombolysis In Myocardial Infarction (TIMI) Study Group was performed to determine the impact of sex on cardiovascular outcomes in this dataset.Ten TIMI trials were identified that enrolled2,500 patients with NSTEACS within 30 days of hospitalization. Cox proportional hazards models were used to examine the association of sex with major adverse cardiovascular events (MACE) (cardiovascular death, myocardial infarction, or stroke) after adjusting for relevant risk factors in individual trials; point estimates were then combined by using random effects models. Individual components of the composite outcome and all-cause mortality were also analyzed.Among 68,730 patients with NSTEACS, 19,827 (29%) were women. Women were older and more frequently had hypertension, diabetes, prior heart failure, and renal impairment than men. Before considering relevant confounders, women were at similar risk of MACE compared with men (hazard ratio [HR]: 1.04; 95% confidence interval [CI]: 0.99 to 1.09; p = 0.16) but at higher risk of all-cause death (HR: 1.12; 95% CI: 1.01 to 1.24; p = 0.03). After adjustment for baseline differences, risks of MACE (HR: 0.93; 95% CI: 0.88 to 0.98; p 0.01) and all-cause death (HR: 0.84; 95% CI: 0.78 to 0.90; p 0.0001) were lower among women compared with men.After accounting for cardiovascular risk factors, women enrolled in clinical trials were at lower risk of MACE than men after NSTEACS. Women, however, remain undertreated with many evidence-based therapies.
- Published
- 2019
9. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS–TIMI 54
- Author
-
Ph. Gabriel Steg, Marc P. Bonaca, Eugene Braunwald, Deepak L. Bhatt, Sabina A. Murphy, Marc S. Sabatine, Dominick J. Angiolillo, Marc Cohen, Sameer Bansilal, Robert F. Storey, KyungAh Im, and Peter Held
- Subjects
Male ,Ticagrelor ,medicine.medical_specialty ,Acute coronary syndrome ,Adenosine ,Myocardial Infarction ,Coronary Disease ,Hemorrhage ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus ,Internal medicine ,Diabetes Mellitus ,Secondary Prevention ,medicine ,Humans ,cardiovascular diseases ,030212 general & internal medicine ,Myocardial infarction ,Stroke ,Aged ,Secondary prevention ,Dose-Response Relationship, Drug ,business.industry ,Middle Aged ,medicine.disease ,Purinergic P2Y Receptor Antagonists ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Mace ,TIMI ,medicine.drug - Abstract
Patients with diabetes appear to be at elevated risk of atherothrombotic events.The purpose of this study was to determine the effect of antiplatelet therapy with ticagrelor on recurrent ischemic events in patients with diabetes and prior myocardial infarction (MI).We examined the subgroups of patients with diabetes (n = 6,806) and without diabetes (n = 14,355) from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54), in which 21,162 patients with a history of MI 1 to 3 years prior and with additional risk factors were randomized to ticagrelor (90 or 60 mg twice daily) or placebo. Patients were followed for a median of 33 months. The primary efficacy endpoint was major adverse cardiovascular events (MACE) (cardiovascular death, MI, stroke) and the primary safety endpoint was TIMI (Thrombolysis In Myocardial Infarction) major bleeding.The relative risk reduction in MACE with ticagrelor was consistent for the pooled doses versus placebo in patients with diabetes (hazard ratio [HR]: 0.84; 95% confidence interval [CI]: 0.72 to 0.99; p = 0.035) and without diabetes (HR: 0.84; 95% CI: 0.74 to 0.96; p = 0.013; p interaction = 0.99). As patients with diabetes were at higher risk of MACE, the absolute risk reduction tended to be greater in patients with versus without diabetes (1.5% vs. 1.1%, with corresponding 3-year number needed to treat of 67 vs. 91). In patients with diabetes requiring pharmacological therapy (n = 5,960), the absolute risk reduction was 1.9% with a 3-year number needed to treat of 53. Additionally, in patients with diabetes, ticagrelor reduced cardiovascular death by 22% and coronary heart disease death by 34%. Similar to patients without diabetes, there was increased TIMI major bleeding in patients with diabetes (HR: 2.56; 95% CI: 1.52 to 4.33; p = 0.0004).In patients with diabetes with prior MI, adding ticagrelor to aspirin significantly reduces the risk of recurrent ischemic events, including cardiovascular and coronary heart disease death. (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin [PEGASUS]; NCT01225562).
- Published
- 2016
10. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome
- Author
-
Daniel Isaza, Craig J. Reist, KyungAh Im, Jennifer A. White, Andrew M. Tershakovec, Robert P. Giugliano, Eugene Braunwald, Michael A. Blazing, Christopher P. Cannon, Mikael Dellborg, Erin A. Bohula, Sabina A. Murphy, Uma Kher, Yuliya Lokhnygina, and Jose Lopez-Sendon
- Subjects
medicine.medical_specialty ,Acute coronary syndrome ,business.industry ,Unstable angina ,030204 cardiovascular system & hematology ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Ezetimibe ,Simvastatin ,Internal medicine ,Cardiology ,Clinical endpoint ,Medicine ,Ezetimibe/simvastatin ,030212 general & internal medicine ,Myocardial infarction ,business ,Cardiology and Cardiovascular Medicine ,Stroke ,medicine.drug - Abstract
Background Intensive low-density lipoprotein cholesterol therapy with ezetimibe/simvastatin in IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) significantly reduced the first primary endpoint (PEP) in patients post-acute coronary syndrome (ACS) compared to placebo/simvastatin. Objectives This analysis tested the hypothesis that total events, including those beyond the first event, would also be reduced with ezetimibe/simvastatin therapy. Methods All PEP events (cardiovascular [CV] death, myocardial infarction [MI], stroke, unstable angina [UA] leading to hospitalization, coronary revascularization ≥30 days post-randomization) during a median 6-year follow-up were analyzed in patients randomized to receive ezetimibe/simvastatin or placebo/simvastatin in IMPROVE-IT. Negative binomial regression was used for the primary analysis. Results Among 18,144 patients, there were 9,545 total PEP events (56% were first events and 44% subsequent events). Total PEP events were significantly reduced by 9% with ezetimibe/simvastatin vs placebo/simvastatin (incidence-rate ratio [RR]: 0.91; 95% confidence interval [CI]: 0.85 to 0.97; p = 0.007), as were the 3 pre-specified secondary composite endpoints and the exploratory composite endpoint of CV death, MI, or stroke (RR: 0.88; 95% CI: 0.81 to 0.96; p = 0.002). The reduction in total events was driven by decreases in total nonfatal MI (RR: 0.87; 95% CI: 0.79 to 0.96; p = 0.004) and total NF stroke (RR: 0.77; 95% CI: 0.65 to 0.93; p = 0.005). Conclusions Lipid-lowering therapy with ezetimibe plus simvastatin improved clinical outcomes. Reductions in total PEP events, driven by reductions in MI and stroke, more than doubled the number of events prevented compared with examining only the first event. These data support continuation of intensive combination lipid-lowering therapy after an initial CV event. (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial [IMPROVE-IT]; NCT00202878 )
- Published
- 2016
- Full Text
- View/download PDF
11. SEX AND PERMANENT DRUG DISCONTINUATION IN CLINICAL TRIALS: INSIGHTS FROM THE TIMI TRIALS
- Author
-
KyungAh Im, Elliott M. Antman, C. Michael Gibson, Eugene Braunwald, Benjamin M. Scirica, Emily S. Lau, Marc S. Sabatine, Michelle L. O'Donoghue, Erin A. Bohula, Jianping Guo, Deepak L. Bhatt, Robert P. Giugliano, Christopher P. Cannon, and David A. Morrow
- Subjects
Clinical trial ,medicine.medical_specialty ,Study drug ,business.industry ,Drug discontinuation ,Internal medicine ,Medicine ,Cardiology and Cardiovascular Medicine ,business ,TIMI ,Odds - Abstract
Women are underrepresented across cardiovascular clinical trials. Whether women are more likely than men to prematurely discontinue study drug is unknown. Eleven phase 3 TIMI trials were included [135,879 men and 51,812 women (28%)]. The association between sex and odds of premature study drug
- Published
- 2020
12. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease
- Author
-
Marc P. Bonaca, Eva C. Jensen, Frederic Kontny, Deepak L. Bhatt, Robert F. Storey, Daniel Isaza, Alexander Parkhomenko, Assen Goudev, Sameer Bansilal, KyungAh Im, Sabina A. Murphy, Dominick J. Angiolillo, Róbert Gábor Kiss, Jose Lopez-Sendon, Ph. Gabriel Steg, Eugene Braunwald, A.J. Oude Ophuis, Marc S. Sabatine, Jan H. Cornel, and Peter Held
- Subjects
Male ,medicine.medical_specialty ,Ticagrelor ,Myocardial Infarction ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Drug Administration Schedule ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Secondary Prevention ,Humans ,cardiovascular diseases ,030212 general & internal medicine ,Myocardial infarction ,Stroke ,Aged ,Aspirin ,business.industry ,Vascular disease ,Hazard ratio ,Thrombosis ,Middle Aged ,medicine.disease ,cardiovascular system ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Intracranial Hemorrhages ,TIMI ,Mace ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
Background Patients with prior myocardial infarction (MI) and multivessel coronary disease (MVD) are at high risk for recurrent coronary events. Objectives The authors investigated the efficacy and safety of ticagrelor versus placebo in patients with MVD in the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis In Myocardial Infarction 54) trial. Methods Patients with a history of MI 1 to 3 years before inclusion in the PEGASUS-TIMI 54 trial were stratified in a pre-specified analysis based on the presence of MVD. The effect of ticagrelor (60 mg and 90 mg) on the composite of cardiovascular death, MI, or stroke (major adverse cardiovascular events [MACE]), as well as the composite of coronary death, MI, or stent thrombosis (coronary events), and on TIMI major bleeding, intracranial hemorrhage (ICH), and fatal bleeding were evaluated over a median of 33 months. Results A total of 12,558 patients (59.4%) had MVD. In the placebo arm, compared with patients without MVD, those with MVD were at higher risk for MACE (9.37% vs. 8.57%, adjusted hazard ratio [HR adj ]: 1.24; p = 0.026) and for coronary events (7.67% vs. 5.34%, HR adj : 1.49; p = 0.0005). In patients with MVD, ticagrelor reduced the risk of MACE (7.94% vs. 9.37%, HR: 0.82; p = 0.004) and coronary events (6.02% vs. 7.67%, HR: 0.76; p Conclusions Patients with prior MI and MVD are at increased risk of MACE and coronary events, and experience substantial relative and absolute risk reductions in both outcomes with long-term ticagrelor treatment relative to those without MVD. Ticagrelor increases the risk of TIMI major bleeding, but not ICH or fatal bleeding. For patients with prior MI and MVD, ticagrelor is an effective option for long-term antiplatelet therapy. (Prevention of Cardiovascular Events [e.g., Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin [PEGASUS]; NCT01225562)
- Published
- 2017
13. Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54
- Author
-
Marc P. Bonaca, Mikhail Rudah, P. Gabriel Steg, Assen Goudev, Robert F. Storey, Sabina A. Murphy, KyungAh Im, Giulia Magnani, Pierre Theroux, Deepak L. Bhatt, Eva C. Jensen, Eugene Braunwald, Gabriel Kamensky, Daniel Isaza, Per Johanson, Marc Cohen, Alexander Parkhomenko, Marc S. Sabatine, Gilles Montalescot, and Ton Oude Ophuis
- Subjects
Male ,medicine.medical_specialty ,Ticagrelor ,Adenosine ,Time Factors ,Population ,Myocardial Infarction ,030204 cardiovascular system & hematology ,Placebo ,Global Health ,03 medical and health sciences ,Electrocardiography ,0302 clinical medicine ,Internal medicine ,Cause of Death ,medicine ,Humans ,Thrombolytic Therapy ,030212 general & internal medicine ,Myocardial infarction ,education ,Stroke ,Aged ,Aspirin ,education.field_of_study ,Dose-Response Relationship, Drug ,business.industry ,Hazard ratio ,Middle Aged ,medicine.disease ,Survival Rate ,Treatment Outcome ,Cardiology ,Purinergic P2Y Receptor Antagonists ,Female ,Cardiology and Cardiovascular Medicine ,business ,TIMI ,medicine.drug ,Follow-Up Studies - Abstract
Background Ticagrelor reduces ischemic risk in patients with prior myocardial infarction (MI). It remains unclear whether ischemic risk and the benefits of prolonged P2Y12 inhibition in this population remain consistent over time. Objectives The study sought to investigate the pattern of ischemic risk over time and whether the efficacy and safety of ticagrelor were similar early and late after randomization. Methods The PEGASUS-TIMI (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis In Myocardial Infarction) 54 trial randomized patients with prior MI (median 1.7 years prior) to ticagrelor 90 mg, ticagrelor 60 mg, or placebo on a background of aspirin. The rates of cardiovascular (CV) death, MI, and stroke as well as TIMI major bleeding were analyzed at yearly landmarks (years 1, 2, and 3). Results A total of 21,162 patients were randomized and followed for 33 months (median), with 28% of patients ≥5 years from MI at trial conclusion. The risk of CV death, MI, or stroke in the placebo arm remained roughly constant over the trial at an ∼3% annualized rate. The benefit of ticagrelor 60 mg was consistent at each subsequent landmark (year 1 hazard ratio [HR]: 0.82; 95% confidence interval [CI]: 0.67 to 0.99; year 2 HR: 0.90; 95% CI: 0.74 to 1.11; and year 3 HR: 0.79; 95% CI: 0.62 to 1.00). TIMI major bleeding was increased with ticagrelor 60 mg at each landmark, but with the greatest hazard in the first year (year 1 HR: 3.22; year 2 HR: 2.07; year 3 HR: 1.65). Conclusions Patients with a history of MI remain at persistent high risk for CVD, MI, and stroke as late as 5 years after MI. The efficacy of low-dose ticagrelor is consistent over time with a trend toward less excess bleeding. (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin [PEGASUS]; NCT01225562)
- Published
- 2017
14. INTERINDIVIDUAL VARIABILITY IN WEIGHT LOSS WITH LORCASERIN: AN ANALYSIS FROM THE CAMELLIA-TIMI 61 STUDY
- Author
-
Steven O. Smith, Silvio Inzucchi, Wenfeng Miao, Arman Qamar, Stephen D. Wiviott, Christina Fanola, Tushar Patel, KyungAh Im, Benjamin M. Scirica, Erin A. Bohula, Darren K. McGuire, Marc S. Sabatine, Carlos Perdomo, Anthony Keech, and Sabina A. Murphy
- Subjects
Agonist ,medicine.drug_class ,business.industry ,Pharmacology ,Placebo ,Lorcaserin ,Lifestyle modification ,Weight loss ,medicine ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,TIMI ,medicine.drug - Abstract
Lorcaserin, a 5HT2c agonist, safely facilitates weight (wt.) loss with favorable effects on cardiometabolic profile. The interindividual variability in wt. loss in response to lorcaserin on a background of lifestyle modification is not well-characterized. CAMELLIA-TIMI 61 was a randomized, placebo
- Published
- 2019
15. PERSISTENCE OF VALVULOPATHY IN THE CAMELLIA-TIMI 61 TRIAL OF LORCASERIN IN OBESE OR OVERWEIGHT PATIENTS AT INCREASED CARDIOVASCULAR RISK
- Author
-
Benjamin M. Scirica, Darren McGuire, Tushar Patel, Stephen D. Wiviott, Anthony Keech, Neil Weissman, Arman Qamar, KyungAh Im, Silvio Inzucchi, Marc S. Sabatine, Steven Smith, Wenfeng Miao, Christina L. Fanola, Carlos Perdomo, Julia F Kuder, and Erin A. Bohula
- Subjects
Agonist ,medicine.medical_specialty ,medicine.drug_class ,business.industry ,Serotonin 2C Receptor ,Overweight ,Lorcaserin ,Persistence (computer science) ,Increased risk ,Weight loss ,Internal medicine ,medicine ,Cardiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,TIMI ,medicine.drug - Abstract
Lorcaserin, a serotonin 2C receptor agonist, recently demonstrated sustained weight loss without an increased risk of cardiovascular (CV) events or valvulopathy in obese or overweight pts at high CV risk. Here we evaluate the persistence of valvulopathy measures. The CAMELLIA-TIMI 61 trial
- Published
- 2019
16. TCT-78 Efficacy of Long-Term Ticagrelor in Stented Patients in PEGASUS-TIMI 54
- Author
-
Philippe Gabriel Steg, KyungAh Im, Eugene Braunwald, Jindrich Spinar, Sameer Bansilal, Peter Held, Deepak L. Bhatt, Eva C. Jensen, Robert F. Storey, Róbert Gábor Kiss, Rafael Diaz, Andrej Budaj, Christian W. Hamm, Gilles Montalescot, Frans Van de Werf, Giulia Magnani, Marc P. Bonaca, Michael Ruda, Marc S. Sabatine, and T. Oude Ophuis
- Subjects
medicine.medical_specialty ,Randomization ,business.industry ,medicine.medical_treatment ,Stent ,030204 cardiovascular system & hematology ,equipment and supplies ,medicine.disease ,3. Good health ,03 medical and health sciences ,surgical procedures, operative ,0302 clinical medicine ,Internal medicine ,Conventional PCI ,medicine ,Cardiology ,In patient ,cardiovascular diseases ,030212 general & internal medicine ,business ,Cardiology and Cardiovascular Medicine ,Stroke ,Ticagrelor ,TIMI ,medicine.drug - Abstract
Ticagrelor in patients with prior MI reduced the incidence of CV death, MI, or stroke by 15-16% in PEGASUS-TIMI 54. We investigated the efficacy of ticagrelor in patients based on the presence and type of stent. Details of each patient's most recent PCI were collected at randomization. Stent
- Published
- 2015
- Full Text
- View/download PDF
17. INFLAMMATORY AND CARDIAC BIOMARKERS ARE ASSOCIATED WITH RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM SAVOR-TIMI 53
- Author
-
Yared Gurmu, KyungAh Im, David A. Morrow, Eugene Braunwald, Ofri Mosenzon, Deepak L. Bhatt, Benjamin M. Scirica, Avivit Cahn, Itamar Raz, and Thomas A Zelniker
- Subjects
medicine.medical_specialty ,business.industry ,Cardiac biomarkers ,nutritional and metabolic diseases ,Type 2 Diabetes Mellitus ,macromolecular substances ,Type 2 diabetes ,medicine.disease ,Roche Diagnostics ,Serum samples ,Internal medicine ,medicine ,In patient ,cardiovascular diseases ,Cardiology and Cardiovascular Medicine ,business ,TIMI - Abstract
Cardiac and renal diseases are commonly intertwined with bidirectional interactions in patients (pts) with type 2 diabetes (T2DM). In this analysis from SAVOR-TIMI 53, hsCRP, NT-proBNP and hsTnT (Roche Diagnostics) were measured in all available serum samples from pts at baseline (n=12,310). The
- Published
- 2018
18. BASELINE RENAL FUNCTION AND CARDIOVASCULAR RISK IN PATIENTS TREATED WITH SAXAGLIPTIN: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL
- Author
-
Matthew A. Cavender, Jaime Davidson, Jacob A. Udell, Benjamin M. Scirica, Philippe Steg, Deepak L. Bhatt, KyungAh Im, Boaz Hirshberg, Ofri Mosenzon, and Itamar Raz
- Subjects
medicine.medical_specialty ,business.industry ,Renal function ,Saxagliptin ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Cardiology ,Medicine ,In patient ,business ,Baseline (configuration management) ,Cardiology and Cardiovascular Medicine ,TIMI - Published
- 2014
- Full Text
- View/download PDF
19. EFFICACY AND SAFETY OF TICAGRELOR AS LONG-TERM SECONDARY PREVENTION IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION AND PERIPHERAL ARTERY DISEASE
- Author
-
Marc P. Bonaca, Eva C. Jensen, Marc S. Sabatine, Marc Cohen, Robert F. Storey, Julia F Kuder, Deepak L. Bhatt, KyungAh Im, Eugene Braunwald, Philippe Steg, and Peter Held
- Subjects
Secondary prevention ,medicine.medical_specialty ,business.industry ,Arterial disease ,Disease ,030204 cardiovascular system & hematology ,medicine.disease ,body regions ,03 medical and health sciences ,0302 clinical medicine ,Concomitant ,Internal medicine ,Cardiology ,Medicine ,In patient ,030212 general & internal medicine ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business ,Ticagrelor ,medicine.drug - Abstract
Peripheral artery disease (PAD) has been associated with heightened ischemic and bleeding risk. In PEGASUS-TIMI 54, a contemporary trial of pts with prior MI, we evaluated ischemic and bleeding risk by concomitant PAD and whether the efficacy and safety of ticagrelor was modified by PAD. PEGASUS
- Published
- 2016
20. CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL
- Author
-
Ravi B. Patel, Lawrence Leiter, Ofri Mosenzon, Eugene Braunwald, KyungAh Im, Estella Kanevsky, Benjamin M. Scirica, Ilaria Cavallari, Darren McGuire, Deepak L. Bhatt, Philippe Steg, and Itamar Raz
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,business.industry ,030209 endocrinology & metabolism ,Type 2 diabetes ,030204 cardiovascular system & hematology ,medicine.disease ,Sudden cardiac death ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,hemic and lymphatic diseases ,Diabetes mellitus ,Internal medicine ,medicine ,Cardiology ,cardiovascular diseases ,Cardiology and Cardiovascular Medicine ,business ,TIMI - Abstract
Even though diabetes is associated with risk of sudden cardiac death (SCD), the actual risk factors for SCD in diabetes have not been well described. Deaths were adjudicated by a blinded events committee in SAVOR-TIMI 53, a randomized trial of type 2 diabetes (T2D) patients with established
- Published
- 2016
21. REDUCTION IN ISCHEMIC EVENTS WITH TICAGRELOR IN DIABETIC PATIENTS FROM THE PEGASUS-TIMI 54 TRIAL
- Author
-
Marc P. Bonaca, Deepak L. Bhatt, Sameer Bansilal, Marc S. Sabatine, Marc Cohen, Eugene Braunwald, Ph. Gabriel Steg, Peter Held, Sabina A. Murphy, KyungAh Im, and Robert F. Storey
- Subjects
medicine.medical_specialty ,business.industry ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Cardiology ,cardiovascular diseases ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,business ,Ticagrelor ,TIMI ,medicine.drug - Abstract
Antiplatelet therapy can play an important role in reducing the risk of recurrent ischemic events in diabetic patients with prior MI. We examined the diabetic subgroup (N= 6806) from PEGASUS-TIMI 54, in which 21,162 patients with a history of MI 1-3 years prior were randomized to ticagrelor (90 mg
- Published
- 2016
22. PROGNOSTIC UTILITY OF FIBROBLAST GROWTH FACTOR-23 AFTER AN ACUTE CORONARY SYNDROME
- Author
-
Mary Ann Lukas, Marc S. Sabatine, Eugene Braunwald, Jing Zhou, Jacob A. Udell, Michelle O’Donoghue, David A. Morrow, Christopher P. Cannon, Petr Jarolim, Christian Hamm, Dylan Steen, KyungAh Im, and Andrzej Budaj
- Subjects
Fibroblast growth factor 23 ,Acute coronary syndrome ,medicine.medical_specialty ,Plaque instability ,business.industry ,medicine.disease ,Fibroblast growth factor ,Internal medicine ,Stable cad ,Cardiology ,Medicine ,Myocardial fibrosis ,In patient ,Cardiology and Cardiovascular Medicine ,business - Abstract
Fibroblast growth factor (FGF)-23 is a phosphatonin that may promote myocardial fibrosis and atherothrombotic plaque instability. Higher FGF-23 levels are associated with adverse cardiovascular (CV) events in stable CAD. The prognostic utility of FGF-23 in patients after an acute coronary syndrome (
- Published
- 2015
23. GALECTIN-3 FOR HEART FAILURE RISK STRATIFICATION IN PATIENTS AFTER ACUTE CORONARY SYNDROMES (ACS): INSIGHTS FROM THE SOLID-TIMI 52 TRIAL
- Author
-
Michelle L. O'Donoghue, Robbert J. de Winter, Petr Jarolim, Harvey D. White, Christopher P. Cannon, KyungAh Im, Eugene Braunwald, Giulia Magnani, Jing Zhou, David A. Morrow, Basil S. Lewis, Dylan L Steen, and Mary Ann Lukas
- Subjects
medicine.medical_specialty ,Galectin-3 ,business.industry ,Internal medicine ,Heart failure ,Risk stratification ,medicine ,Cardiology ,In patient ,Cardiology and Cardiovascular Medicine ,medicine.disease ,business ,TIMI - Published
- 2015
24. CARDIOVASCULAR EVENT RATES IN PATIENTS WITH DIABETES: INSIGHTS FROM THE INTERNATIONAL REACH REGISTRY
- Author
-
Sidney C. Smith, KyungAh Im, Julia F Kuder, Philippe Gabriel Steg, Erik Magnus Ohman, Shinya Goto, Matthew A. Cavender, Kim A. Eagle, and Deepak L. Bhatt
- Subjects
Cardiovascular event ,medicine.medical_specialty ,business.industry ,Diabetes mellitus ,Emergency medicine ,medicine ,In patient ,Medical emergency ,Cardiology and Cardiovascular Medicine ,medicine.disease ,business - Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.